H. Lundbeck A/S Company Profile

06:34 EDT 23rd March 2019 | BioPortfolio

We are a research-based company. We engage in research to find new drugs for treatment of CNS disorders, includ­ing depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease.These are serious disorders. They affect not only patients, but also their families and friends. Besides the stress of having a CNS disorder, patients are often exposed to prejudice because, in many sections of society, there is still far too little understanding of how adversely a CNS disorder affects an individual’s life.
We have taken upon ourselves the task of improving quality of life for persons with a psychiatric or neurological disorder, and we are working intensely to find and develop new and improved drugs. We believe that we can make a significant difference, and we are happy to do so in cooperation with others.


Ottiliavej 9


Phone: 45 36 30 13 11
Fax: 45 36 30 19 40

News Articles [81 Associated News Articles listed on BioPortfolio]

Otsuka and Lundbeck report positive brexpiprazole results

Otsuka Pharmaceutical and Lundbeck have reported positive results from three Phase III studies evaluating the safety and efficacy of brexpiprazole...Read More... The post Otsuka and Lundbeck report po...

Lundbeck and Otsuka Announce Positive Phase 2 Data for Combination Treatment of Brexpiprazole and Sertraline in Post-Traumatic Stress Disorder

Valby, Denmark and Tokyo, Japan, 30 November 2018 – H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today the achievement of positive clinical results (in inte...

Lundbeck partners with Elsevier to accelerate research into brain disorders

Global pharma player Lundbeck has announced a project with information analytics company Elsevier to help it improve the way it manages data and ultimately speed up drug development.

Lundbeck joins with Elsevier to help manage R&D data

Denmark's Lundbeck has signed an agreement with information business Elsevier, that aims to help organise the masses of scientific data it has available, and make drug research more productive and eff...

Caesar @CaesarBiotech

@semodough It could only in this field..……

Lundbeck craters as resistant schizophrenia drug fails phase III

Danish drugmaker Lundbeck saw more than a quarter of the value wiped off its shares yesterday after its top pipeline prospect, a drug for schizophrenia, missed the mark in a phase III trial. In the 1...

The Darkest Hour Is After DAYBREAK For Lundbeck’s New Antipsychotic

The first Phase III study for Lundbeck’s novel antipsychotic flops leaving the Danish company shares down by 25% as investors...   

VIDEO: Lundbeck Still Assessing Future Of Antipsychotic After Phase III Failure, Says CEO

Deborah Dunsire, Lundbeck’s new CEO, talks to Scrip about the fallout from its recent Phase III setback, and how she...   

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Atryn [lundbeck inc.]

These highlights do not include all the information needed to use ATryn safely and effectively. See full prescribing information for ATryn. ATryn, Antithrombin (Recombinant) Lyophilized powder for rec...

Northera [lundbeck pharmaceuticals llc]

These highlights do not include all the information needed to use NORTHERA® safely and effectively. See full prescribing information for NORTHERA. NORTHERA® (droxidopa) capsules, for oral useInitia...

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Multiple-therapy-resistant major depressive disorder: a clinically important concept.

SummaryMany novel therapeutic options for depression exist that are either not mentioned in clinical guidelines or recommended only for use in highly specialist services. The challenge faced by clinic...

Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia.

Treatment-resistant schizophrenia (TRS) occurs in approximately 30% of individuals diagnosed with schizophrenia. The identification and management of TRS in clinical practice are inconsistent and not ...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

The purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of Parkinson disease. This study will be performed in ...

Companies [18 Associated Companies listed on BioPortfolio]

Lundbeck LLC

Lundbeck in the U.S., headquartered in Deerfield, Illinois, is a wholly-owned subsidiary of H. Lundbeck A/S in Denmark. Lundbeck is committed to accelerating advances in brain dis...

Lundbeck Inc.

Lundbeck Inc. was established in March 2009 following the acquisition of Ovation Pharmaceuticals, Inc. by Lundbeck and has proven success in developing and commercializing high-ne...


Depression, schizophrenia, Alzheimer's, Parkinson's, epilepsy, Multiple Sclerosis, and migraines have their foundation in the Central Nervous System - our key focus areas. Lundbeck's entire R&D effort...


The Lundbeck Institute is pleased to present Psychotropics Online, a comprehensive guide to CNS compounds and products.We have published Psychotropics since the 1960s in a printed handbook version, an...

Lundbeck Limited

As a pharmaceutical manufacturer, Lundbeck is unique in that we focus solely on the treatment of diseases of the central nervous system. Our aim is to be the world leader in the development of pharmac...

More Information about "H. Lundbeck A/S" on BioPortfolio

We have published hundreds of H. Lundbeck A/S news stories on BioPortfolio along with dozens of H. Lundbeck A/S Clinical Trials and PubMed Articles about H. Lundbeck A/S for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of H. Lundbeck A/S Companies in our database. You can also find out about relevant H. Lundbeck A/S Drugs and Medications on this site too.

Quick Search


Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Schizophrenia is a common  serious long-term mental health condition that affects 5 in 1000 in the UK. It causes a range of different psychological symptoms; hallucinations, delusions, muddled thoughts based on the hallucinations or delusions and ch...

Corporate Database Quicklinks

Searches Linking to this Company Record